A Study to Evaluate the Safety and Immune Response to an Unadjuvanted RSV Maternal Vaccine in Healthy Non-pregnant Females From 9 to 49 Years of Age

NCT05169905 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

9

Enrollment

INDUSTRY

Sponsor class

Conditions

Respiratory Syncytial Virus Infections

Interventions

COMBINATION_PRODUCT: RSV MAT vaccine
COMBINATION_PRODUCT: dTpa vaccine

Sponsor

GlaxoSmithKline